Bellicum Pharmaceuticals has suffered a setback with its trials of an experimental cancer drug.
Earlier this week the Houston-based biotech firm announced that the FDA has placed a clinical hold on four U.S. studies of BPX-501, a new cellular immunotherapy for cancer and orphan inherited blood disorders. The agency made the move after three patients in the studies developed brain disorder, possibly related to the treatment.
Bellicum reported that there could be several factors affecting the cases, and that it’s working with the FDA to resolve the issues.
Read the full report.